February 24, 2026 – Pittsburgh, Pennsylvania, USA
Consegna Pharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has provided written feedback following a Type C regulatory meeting regarding CP217, the company’s investigational long-acting naloxone injectable being developed to prevent renarcotization after emergency opioid overdose reversal.
The Agency concurred with Consegna’s proposed modeling and simulation (M&S)–driven clinical development strategy, recognizing it as an appropriate scientific framework to support the regulatory pathway for this novel indication. Renarcotization, a life-threatening recurrence of opioid toxicity after initial naloxone rescue, remains a critical challenge in overdose management, particularly with high-potency synthetic opioids such as fentanyl. CP217 is designed to provide sustained opioid receptor antagonism lasting 12–24 hours, addressing the gap between short-acting naloxone rescue and prolonged opioid effects.
Modeling-Driven Development Gains FDA Alignment
The FDA’s feedback validated Consegna’s proprietary in silico mechanistic modeling platform, which simulates opioid overdose physiology, respiratory depression dynamics, and renarcotization risk across large virtual patient populations. This Model-Informed Drug Development (MIDD) approach allows researchers to generate robust evidence on therapeutic exposure, dosing optimization, and clinical effect while reducing reliance on extensive efficacy trials.
Regulators agreed that the proposed labeling indication—prevention of renarcotization when residual opioid activity outlasts rescue treatment—represents a clinically meaningful therapeutic objective. The Agency further indicated that substantial evidence of effectiveness could be supported through an integrated data package combining modeling simulations, pharmacokinetics, bioavailability, and clinical safety findings.
Advertisement
This alignment signals growing regulatory acceptance of advanced computational science in accelerating drug development, particularly in emergency medicine settings where traditional placebo-controlled trials may be impractical or ethically complex.
505(b)(2) Pathway Supports Accelerated Approval
In its written responses, the FDA confirmed that the 505(b)(2) regulatory pathway appears appropriate for CP217. This hybrid approval route allows sponsors to leverage existing safety and efficacy data from reference listed drugs—in this case, naloxone—while submitting new evidence supporting differentiated formulations or indications.
To establish a scientific bridge, Consegna will conduct comparative pharmacokinetic studies evaluating drug absorption, exposure duration, and receptor blockade relative to standard naloxone therapies. The company indicated that a focused bioavailability and safety clinical study will serve as the central human trial component within its streamlined development program.
By integrating long-acting drug delivery technology with modeling-driven analytics, CP217 represents a first-of-its-kind application of simulation-supported regulatory science within opioid overdose prevention. This capital-efficient strategy may significantly shorten development timelines while maintaining rigorous scientific validation.
Long-Acting Naloxone Targets Fentanyl Crisis
CP217 is formulated as a microencapsulated injectable naloxone hydrochloride, engineered to release the opioid antagonist gradually following administration. The sustained exposure profile is designed to counteract potent synthetic opioids such as fentanyl, whose pharmacologic effects often outlast conventional naloxone rescue doses.
The development program has received support from the National Institute on Drug Abuse (NIDA), reflecting public health urgency surrounding opioid mortality. Long-acting overdose reversal agents are increasingly viewed as critical tools in reducing post-rescue fatality risk, particularly in community and emergency response environments.
Consegna’s broader pipeline applies quantitative clinical pharmacology and long-acting delivery platforms across addiction medicine, substance use disorder treatment, and non-opioid pain therapeutics. CP217 remains its lead emergency response asset targeting overdose survival outcomes.
With FDA concurrence on its modeling framework and regulatory pathway, Consegna is advancing toward future New Drug Application (NDA) submission, while exploring strategic partnerships to expand clinical and commercial impact. The regulatory milestone underscores how computational drug development, extended-release pharmacology, and public health innovation are converging to address one of the most urgent medical crises of the modern era.
Source: Consegna Pharma press release
